SOPHiA GENETICS Says Mount Sinai Health System to Adopt Its Platform for Cancer Genomic Testing
MT Newswires Live
Apr 16
SOPHiA GENETICS (SOPH) said Thursday that Mount Sinai Health System will adopt its SOPHiA DDM platform to support cancer research and expand genomic testing capabilities.
The company said Mount Sinai's molecular pathology team plans to use the artificial intelligence-powered platform to strengthen next-generation sequencing analysis for both blood cancers and solid tumors, helping detect and interpret complex genomic variants more efficiently.
Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center that treats more than 4,000 oncology patients annually, is expected to use the platform to streamline laboratory workflows and reduce manual interpretation time, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.